For example, the OASIS-4 trial showed an average weight loss of 13.6% with the maximum 25 mg dose, which takes 4 months to reach under the licensed dosing protocol
Carillo, M
Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial
The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), a phase 3 study involving 17,604 adults with overweight or obesity and pre-existing CVD but no diabetes, revealed that once-weekly subcutaneous semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared with placebo over a mean follow-up of 39.8 months, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [48]
Regular check-ins allow your provider to assess your response and adjust your protocol as needed
SIDE EFFECTS AND PRECAUTIONS On rare ocassions: allergic reactions, mainly in the form of skin rash